156 related articles for article (PubMed ID: 30903640)
1. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
[TBL] [Abstract][Full Text] [Related]
2. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.
Pandya H; Gibo DM; Garg S; Kridel S; Debinski W
Neuro Oncol; 2012 Jan; 14(1):6-18. PubMed ID: 21946118
[TBL] [Abstract][Full Text] [Related]
3. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide.
Jannoo R; Xia Z; Row PE; Kanamarlapudi V
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830725
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
6. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.
Fujisawa T; Joshi B; Nakajima A; Puri RK
Cancer Res; 2009 Nov; 69(22):8678-85. PubMed ID: 19887609
[TBL] [Abstract][Full Text] [Related]
7. HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo.
Kawamoto M; Horibe T; Kohno M; Kawakami K
Mol Cancer Ther; 2013 Apr; 12(4):384-93. PubMed ID: 23358664
[TBL] [Abstract][Full Text] [Related]
8. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
Yang L; Horibe T; Kohno M; Haramoto M; Ohara K; Puri RK; Kawakami K
Mol Cancer Ther; 2012 Jan; 11(1):235-43. PubMed ID: 22084165
[TBL] [Abstract][Full Text] [Related]
9. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.
Tu M; Wange W; Cai L; Zhu P; Gao Z; Zheng W
Tumour Biol; 2016 Nov; 37(11):14701-14709. PubMed ID: 27623944
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma.
Seto K; Shoda J; Horibe T; Warabi E; Ishige K; Yamagata K; Kohno M; Yanagawa T; Bukawa H; Kawakami K
Oncol Rep; 2013 Jun; 29(6):2147-53. PubMed ID: 23563734
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
12. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Fujisawa T; Joshi BH; Puri RK
Int J Cancer; 2012 Jul; 131(2):344-56. PubMed ID: 21858811
[TBL] [Abstract][Full Text] [Related]
13. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
14. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.
Kawamoto M; Horibe T; Kohno M; Kawakami K
BMC Cancer; 2011 Aug; 11():359. PubMed ID: 21849092
[TBL] [Abstract][Full Text] [Related]
15. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.
Hsi LC; Kundu S; Palomo J; Xu B; Ficco R; Vogelbaum MA; Cathcart MK
Mol Cancer Ther; 2011 Jul; 10(7):1149-60. PubMed ID: 21596889
[TBL] [Abstract][Full Text] [Related]
16. Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects.
Lin XM; Shi XX; Xiong L; Nie JH; Ye HS; Du JZ; Liu J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638961
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
18. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.
Tada N; Horibe T; Haramoto M; Ohara K; Kohno M; Kawakami K
Biochem Biophys Res Commun; 2011 Apr; 407(2):383-8. PubMed ID: 21396910
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
20. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
